This patent stems from a provisional patent application filed with the US Patent and Trademark Office in February 2004 by Quick-Med.
The new patent, together with a previously issued patent and eleven additional pending patent applications plus foreign counterparts pending in Europe, Australia, Brazil, Canada, China, India, Japan, Mexico, and South Africa, provide broad coverage for Nimbus, a next-generation antimicrobial technology.
Quick-Med has already licensed its first product, Nimbus gauze, to Derma Sciences, a provider of advanced wound care products. Derma Sciences will market the product after Quick-Med receives FDA clearance.